P. Amin

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.

Hong Zhang, M. Embry, Y. Chen, 2001, Cancer research.

Advances in Brief Antitumor Synergy of CV 787 , a Prostate Cancer-specific Adenovirus , and Paclitaxel and Docetaxel

M. Embry, Hong Zhang, J. Oh, 2001 .

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.

Hong Zhang, Y. Chen, D. Yu, 2001, Cancer research.

bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.

A. Borkowski, N. Kyprianou, S. Jacobs, 1998, Urology.

Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.

N. Kyprianou, S. Jacobs, P. Amin, 2001, The Journal of urology.